Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

ConverGene has discovered and developed a propriety library of small molecules that have profound effects on the MYC gene, a critical oncogene that controls progression of cancer. From this compound library, we have established our first program to develop novel BRD4 inhibitors.

ConverGene has discovered and developed a propriety library of small molecules that have profound effects on the MYC gene, a critical oncogene that controls progression of cancer. From this compound library, we have established our first program to d...Show all

Company (Alive / Active)

Phone: 301-861-0009

Fax:

22 Firstfield Road
Suite 280
Gaithersburg, 20878
Maryland, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
ConverGene $1.6M Apr 8, 2014

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related ConverGene Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Methods and compositions for inhibition of bromodomain-containing proteins Mar 13, 2014 Jul 04, 2017 Patent
Methods and compositions for inhibition of bromodomain-containing proteins Jun 27, 2017 Application